LeMaitre Vascular, Inc. $LMAT Stock: Geneva Capital Management LLC Lowers Stake

Geneva Capital Management LLC cut its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report) by 13.2% in the third quarter, HoldingsChannel reports. The firm owned 511,223 shares of the medical instruments supplier’s stock after selling 77,841 shares during the quarter. Geneva Capital Management LLC’s holdings in LeMaitre Vascular were worth $42,222,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of LMAT. Russell Investments Group Ltd. increased its position in LeMaitre Vascular by 1.7% in the third quarter. Russell Investments Group Ltd. now owns 159,868 shares of the medical instruments supplier’s stock worth $13,203,000 after purchasing an additional 2,614 shares during the last quarter. Maryland State Retirement & Pension System lifted its position in LeMaitre Vascular by 53.4% during the third quarter. Maryland State Retirement & Pension System now owns 4,677 shares of the medical instruments supplier’s stock valued at $386,000 after purchasing an additional 1,628 shares during the last quarter. Riverbridge Partners LLC lifted its position in LeMaitre Vascular by 12.6% during the third quarter. Riverbridge Partners LLC now owns 99,596 shares of the medical instruments supplier’s stock valued at $8,226,000 after purchasing an additional 11,129 shares during the last quarter. Summit Creek Advisors LLC lifted its position in LeMaitre Vascular by 0.9% during the third quarter. Summit Creek Advisors LLC now owns 49,624 shares of the medical instruments supplier’s stock valued at $4,098,000 after purchasing an additional 450 shares during the last quarter. Finally, Kornitzer Capital Management Inc. KS grew its stake in shares of LeMaitre Vascular by 11.0% in the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 13,650 shares of the medical instruments supplier’s stock worth $1,127,000 after buying an additional 1,352 shares in the last quarter. Institutional investors own 84.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Barrington Research cut shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 5th. Citigroup restated a “market outperform” rating on shares of LeMaitre Vascular in a research report on Thursday, November 5th. Seaport Research Partners set a $110.00 price target on shares of LeMaitre Vascular in a report on Thursday, November 5th. Wells Fargo & Company dropped their price target on LeMaitre Vascular from $94.00 to $86.00 and set an “equal weight” rating for the company in a research report on Thursday, November 5th. Finally, Wall Street Zen lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Three equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $108.25.

Check Out Our Latest Analysis on LMAT

LeMaitre Vascular Stock Performance

NASDAQ LMAT opened at $78.29 on Monday. The company has a market cap of $1.79 billion, a P/E ratio of 28.47, a P/E/G ratio of 2.31 and a beta of 0.51. The company has a debt-to-equity ratio of 0.39, a quick ratio of 12.54 and a current ratio of 14.60. The business’s 50 day moving average price is $81.31 and its 200-day moving average price is $93.95. LeMaitre Vascular, Inc. has a fifty-two week low of $77.46 and a fifty-two week high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The medical instruments supplier reported $0.65 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.69 by ($0.04). The company had revenue of $67.97 million during the quarter, compared to the consensus estimate of $67.39 million. LeMaitre Vascular had a return on equity of 15.33% and a net margin of 23.51%. The firm’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.75 earnings per share. Sell-side analysts predict that LeMaitre Vascular, Inc. will post 2.83 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Thursday, November 19th will be given a dividend of $0.25 per share. The ex-dividend date is Thursday, November 19th. This represents a $1.00 dividend on an annualized basis and a yield of 1.3%. LeMaitre Vascular’s payout ratio is 36.36%.

About LeMaitre Vascular

(Free Report)

LeMaitre Vascular develops, manufactures and markets medical devices used primarily in the treatment of vascular disease. Its products support procedures performed by vascular surgeons and include vascular grafts, embolectomy catheters, carotid shunts, valvulotomes and other instruments used in vascular surgery. Founded in 1983 by vascular surgeon George LeMaitre, the company is headquartered in Burlington, Massachusetts. Its products are sold to hospitals and medical professionals around the world through a combination of direct sales and distributors.

See Also

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report).

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.